BQL 5

BQL 5 may be available in the countries listed below.

Ingredient matches for BQL 5

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of BQL 5 in the following countries:

• Vietnam

International Drug Name Search

Sigmacort

Sigmacort may be available in the countries listed below.

Ingredient matches for Sigmacort

Hydrocortisone

Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Sigmacort in the following countries:

• Australia

International Drug Name Search

Melitracen Hydrochloride

Melitracen Hydrochloride may be available in the countries listed below.

Ingredient matches for Melitracen Hydrochloride

Melitracen

Melitracen Hydrochloride (USAN) is also known as Melitracen (Rec.INN)

International Drug Name Search

Glossary

Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Lexmox

Lexmox may be available in the countries listed below.

Ingredient matches for Lexmox

Amoxicillin

Amoxicillin is reported as an ingredient of Lexmox in the following countries:

• India

International Drug Name Search

Flusapex

Flusapex may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Flusapex

Furosemide

Furosemide is reported as an ingredient of Flusapex in the following countries:

• Australia

International Drug Name Search

Torax

Torax may be available in the countries listed below.

Ingredient matches for Torax

Ketorolac

Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Torax in the following countries:

• Bangladesh

International Drug Name Search

Mitomicina C Filaxis

Mitomicina C Filaxis may be available in the countries listed below.

Ingredient matches for Mitomicina C Filaxis

Mitomycin

Mitomycin is reported as an ingredient of Mitomicina C Filaxis in the following countries:

• Argentina

International Drug Name Search

Aminfluorid

Aminfluorid may be available in the countries listed below.

Ingredient matches for Aminfluorid

Olaflur

Olaflur is reported as an ingredient of Aminfluorid in the following countries:

• Croatia (Hrvatska)

Sodium Fluoride

Sodium Fluoride is reported as an ingredient of Aminfluorid in the following countries:

• Slovenia

International Drug Name Search

Ciprofloxacina Bottle-Pack

Ciprofloxacina Bottle-Pack may be available in the countries listed below.

Ingredient matches for Ciprofloxacina Bottle-Pack

Ciprofloxacin

Ciprofloxacin is reported as an ingredient of Ciprofloxacina Bottle-Pack in the following countries:

• Colombia

International Drug Name Search

Alogesia

Alogesia may be available in the countries listed below.

Ingredient matches for Alogesia

Ibuprofen

Ibuprofen lysine (a derivative of Ibuprofen) is reported as an ingredient of Alogesia in the following countries:

• Spain

International Drug Name Search

Frontline Plus

Frontline Plus may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Frontline Plus

Fipronil

Fipronil is reported as an ingredient of Frontline Plus in the following countries:

• South Africa

Methoprene

Methoprene S-Methopren (a derivative of Methoprene) is reported as an ingredient of Frontline Plus in the following countries:

• South Africa

International Drug Name Search

Ikagen

Ikagen may be available in the countries listed below.

Ingredient matches for Ikagen

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Ikagen in the following countries:

• Indonesia

International Drug Name Search

Clocardigel

Clocardigel may be available in the countries listed below.

Ingredient matches for Clocardigel

Clopidogrel

Clopidogrel is reported as an ingredient of Clocardigel in the following countries:

• Vietnam

International Drug Name Search

Katenomin

Katenomin may be available in the countries listed below.

Ingredient matches for Katenomin

Atenolol

Atenolol is reported as an ingredient of Katenomin in the following countries:

• Japan

International Drug Name Search

Molsidomin Stada

Molsidomin Stada may be available in the countries listed below.

Ingredient matches for Molsidomin Stada

Molsidomine

Molsidomine is reported as an ingredient of Molsidomin Stada in the following countries:

• Germany

International Drug Name Search

Bisbacter

Bisbacter may be available in the countries listed below.

Ingredient matches for Bisbacter

Bismuth Subsalicylate

Bismuth Subsalicylate is reported as an ingredient of Bisbacter in the following countries:

• Colombia

International Drug Name Search

Prosner

Prosner may be available in the countries listed below.

Ingredient matches for Prosner

Beraprost

Beraprost sodium (a derivative of Beraprost) is reported as an ingredient of Prosner in the following countries:

• Japan

International Drug Name Search

Mepivacaina Diasa

Mepivacaina Diasa may be available in the countries listed below.

Ingredient matches for Mepivacaina Diasa

Mepivacaine

Mepivacaine hydrochloride (a derivative of Mepivacaine) is reported as an ingredient of Mepivacaina Diasa in the following countries:

• Spain

International Drug Name Search

Replens

In the US, Replens (emollients topical) is a member of the drug class topical emollients and is used to treat Dry Skin.

US matches:

• Replens

Ingredient matches for Replens

Polycarbophil

Polycarbophil is reported as an ingredient of Replens in the following countries:

• Canada

International Drug Name Search

Racedot

Racedot may be available in the countries listed below.

Ingredient matches for Racedot

Racecadotril

Racecadotril is reported as an ingredient of Racedot in the following countries:

• Georgia

International Drug Name Search

Ovitrelle

Ovitrelle may be available in the countries listed below.

UK matches:

• Ovitrelle 250 micrograms/0.5 ml prefilled syringe (SPC)

Ingredient matches for Ovitrelle

Chorionic Gonadotrophin

Chorionic Gonadotrophin is reported as an ingredient of Ovitrelle in the following countries:

• Tunisia

Chorionic Gonadotrophin alfa (a derivative of Chorionic Gonadotrophin) is reported as an ingredient of Ovitrelle in the following countries:

• Austria


• Belgium


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Finland


• France


• Germany


• Greece


• Hungary


• Iceland


• Ireland


• Israel


• Italy


• Netherlands


• Norway


• Poland


• Portugal


• Romania


• Russian Federation


• Serbia


• Slovakia


• Slovenia


• Spain


• Sweden


• Switzerland


• Turkey


• United Kingdom


• Vietnam

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Xanturenasi

Xanturenasi may be available in the countries listed below.

Ingredient matches for Xanturenasi

Pyridoxine

Pyridoxine hydrochloride (a derivative of Pyridoxine) is reported as an ingredient of Xanturenasi in the following countries:

• Italy

International Drug Name Search

Induction of Cyclic Withdrawal Bleeding Medications

There are currently no drugs listed for "Induction of Cyclic Withdrawal Bleeding". See Uterine Bleeding.

Drug List:

Spasmogen

Spasmogen may be available in the countries listed below.

Ingredient matches for Spasmogen

Otilonium Bromide

Otilonium Bromide is reported as an ingredient of Spasmogen in the following countries:

• Israel

International Drug Name Search

Rivanol Galen

Rivanol Galen may be available in the countries listed below.

Ingredient matches for Rivanol Galen

Ethacridine

Ethacridine lactate (a derivative of Ethacridine) is reported as an ingredient of Rivanol Galen in the following countries:

• Bulgaria

International Drug Name Search

Sore Throat

Ingredient matches for Sore Throat

Phenol

Phenol is reported as an ingredient of Sore Throat in the following countries:

• United States

International Drug Name Search

Etoposid Hexal

Etoposid Hexal may be available in the countries listed below.

Ingredient matches for Etoposid Hexal

Etoposide

Etoposide is reported as an ingredient of Etoposid Hexal in the following countries:

• Germany

International Drug Name Search

K-Lor

In the US, K-Lor (potassium chloride systemic) is a member of the drug class minerals and electrolytes and is used to treat Hypokalemia and Prevention of Hypokalemia.

US matches:

• K-Lor

Ingredient matches for K-Lor

Potassium Chloride

Potassium Chloride is reported as an ingredient of K-Lor in the following countries:

• United States

International Drug Name Search

Ursodeoxycholic Acid

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A05AA02

CAS registry number (Chemical Abstracts Service)

0000128-13-2

Chemical Formula

C24-H40-O4

Molecular Weight

392

Therapeutic Category

Treatment of cholesterol gallstones

Chemical Name

Cholan-24-oic acid, 3,7-dihydroxy-, (3α,5ß,7ß)-

Foreign Names

• Acidum Ursodeoxycholicum (Latin)
• Ursodeoxycholsäure (German)
• Acide ursodésoxycholique (French)
• Acido ursodeoxicolico (Spanish)

Generic Names

• Acide ursodésoxycholique (OS: DCF)
• Acido ursodesossicolico (OS: DCIT)
• Ursodeoxycholic Acid (OS: BAN)
• Ursodesoxycholic Acid (OS: JAN)
• Ursodiol (OS: USAN)
• UDC (IS)
• UDCA (IS)
• Acide ursodésoxycholique (PH: Ph. Eur. 6)
• Acidum ursodeoxycholicum (PH: Ph. Eur. 6)
• Ursodeoxycholic Acid (PH: BP 2010, JP XIV, Ph. Eur. 6)
• Ursodeoxycholsäure (PH: Ph. Eur. 6)
• Ursodiol (PH: USP 32)
• Acidum ursodeoxycholicum (bis(emisuccinato) disodico) (IS)
• Acidum ursodeoxycholicum bis (IS: natrium succinatum)

Brand Names

• Acido Ursodesossicolico Actavis
  Actavis, Italy



• Acido Ursodesossicolico Angenerico
  Angenerico, Italy



• Acido Ursodesossicolico Doc
  DOC Generici, Italy



• Acido Ursodesossicolico Dorom
  Dorom, Italy



• Acido Ursodesossicolico EG
  EG, Italy



• Acido Ursodesossicolico Mylan
  Mylan, Italy



• Acido Ursodesossicolico ratiopharm
  Ratiopharm, Italy



• Acido Ursodesossicolico Special Product's
  Special Product's, Italy



• Acido Ursodesossicolico Teva
  Teva, Italy



• Acido Ursodesossicolico Winthrop
  Winthrop, Italy



• Actigall
  Novartis, New Zealand; Watson, United States



• Adursal
  Leiras, Finland



• Biliepar
  Ibirn, Italy



• Bilifalk
  Dr Falk, Spain



• Buraue
  Yoshindo, Japan



• Cholit-Ursan
  Stada, Germany



• Coleretik
  Sherfarma, Peru



• Daewoongursa
  Daewoong, Vietnam



• Delursan
  Axcan, France



• Desoxil
  B&G, Italy



• Destolit
  Norgine, United Kingdom; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal



• Destolit (veterinary use)
  Norgine Animalhealth, United Kingdom



• Deursil
  Sanofi-Aventis, Italy



• De-ursil
  Sanofi-Aventis, Switzerland



• Dexo
  Dominguez, Argentina



• Dissolursil
  Farma1, Italy



• Estazor
  Fahrenheit, Indonesia



• Fraurs
  Francia, Italy



• Lithofalk (Ursodeoxycholic Acid and Chenodeoxycholic Acid)
  Falk, Germany



• Litoff
  Caber, Italy



• Litomen
  Best, Colombia



• Litursol
  Crinos, Italy



• PMS-Ursodiol
  Pharmascience, Canada



• Precoat
  Tatsumi Kagaku, Japan



• Proursan
  Pro.Med., Poland



• Reptor
  Fuso Pharmaceutical, Japan



• Solutrat
  Sandoz, Argentina



• Stonex
  Opsonin, Bangladesh



• Ubiron
  Medisa Shinyaku, Japan



• UDC AL
  Aliud, Germany



• UDC Hexal
  Hexal, Germany



• UDCA Ferring
  Ferring, Argentina



• Udiliv
  Solvay, India



• Urchil
  Aamorb, India



• Urdafalk
  Darya-Varia, Indonesia; Falk, Indonesia



• Urdahex
  Kalbe, Indonesia



• Urdenacin
  Taiyo Pharmaceutical, Japan



• Urdes
  Errekappa, Italy



• Urdeston
  Towa Yakuhin, Japan



• Urdex
  Towa Yakuhin, Japan



• Urdox
  CP, Malta; Wockhardt, United Kingdom



• Urdox (veterinary use)
  Wockhardt, United Kingdom



• Urosofalk
  Falk, Portugal



• Ursa 200MG
  Daewoong, Vietnam



• Ursacol
  Zambon, Brazil; Zambon, Colombia; Zambon, Italy



• Ursamic
  Nipro PharmaNipurofama, Japan



• Ursidesox
  Duncan, Argentina



• Ursilon
  IBI, Italy



• Urso Heumann
  Heumann, Germany



• Urso
  Axcan, Canada; Axcan, United States; Mitsubishi, Taiwan; Tanabe Mitsubishi, Japan



• Ursobil
  ABC, Italy



• Ursobilane
  Estedi, Spain



• Ursocam
  Polfarmex, Poland



• Ursochol
  Delphi, Netherlands; Dr. Fisher, Netherlands; EU-Pharma, Netherlands; Eureco, Netherlands; Euro, Netherlands; Zambon, Belgium; Zambon, Switzerland; Zambon, Germany; Zambon, Spain; Zambon, Indonesia; Zambon, Luxembourg; Zambon, Netherlands



• Ursodeoxycholic Acid-Sunve Pharm
  Sunve, China



• Ursodeoxycholzuur Imphos
  Imphos, Netherlands



• Ursodiol Teva
  Elvim, Latvia



• Ursodiol
  Actavis, United States; Bioprogress Pharma, Italy; CorePharma, United States; HLB, Argentina; Lannett, United States; Mylan, United States; Teva USA, United States; Watson, United States



• Ursofalk
  ARIS, Turkey; Biotoscana, Chile; Biotoscana, Colombia; Biotoscana, Peru; Cevallos, Argentina; Codali, Belgium; Codali, Luxembourg; Dr Falk, United Kingdom; Dr Falk, Ireland; Dr. Falk, Norway; Eureco, Netherlands; Ewopharma, Romania; Falk, Bosnia & Herzegowina; Falk, China; Falk, Czech Republic; Falk, Germany; Falk, Estonia; Falk, Georgia; Falk, Hong Kong; Falk, Hungary; Falk, Israel; Falk, Lithuania; Falk, Latvia; Falk, Malta; Falk, Malaysia; Falk, Poland; Falk, Romania; Falk, Serbia; Falk, Singapore; Falk, Slovakia; Falk/Pharmalink, Philippines; Farmasa, Mexico; Galenica, Greece; Meda, Sweden; Merck, Austria; Orphan, Australia; Salus, Slovenia; Tramedico, Netherlands; Vifor, Switzerland; Würth, Croatia (Hrvatska)



• Ursoflor
  So.Se., Italy



• Ursogal
  Galen, United Kingdom



• Ursogal (veterinary use)
  Galen, United Kingdom



• Ursolic
  Gentle, Taiwan; Guardian Pharmatama, Indonesia



• Ursolisin
  Magis, Italy



• Ursolit
  CTS, Israel



• Ursolvan
  Sanofi-Aventis, France



• Ursomax
  Altius, Argentina



• Ursopol
  ICN, Poland



• Ursosan
  Evolan, Sweden; Mitsubishi, Hong Kong; Pro.Med.CS, Bosnia & Herzegowina; Pro.Med.CS, Czech Republic; Pro.Med.CS, Estonia; Pro.Med.CS, Georgia; Pro.Med.CS, Lithuania; Pro.Med.CS, Latvia; Pro.Med.CS, Romania; Pro.Med.CS, Serbia; Pro.Med.CS, Russian Federation; Pro.Med.CS, Slovenia; Pro.Med.CS, Slovakia



• Ursotan
  Sanofi-Aventis, South Africa



• Urzac
  Quesada, Argentina



• Ursodamor
  Damor, Italy

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Foli Doce

Foli Doce may be available in the countries listed below.

Ingredient matches for Foli Doce

Cyanocobalamin

Cyanocobalamin is reported as an ingredient of Foli Doce in the following countries:

• Spain

Folic Acid

Folic Acid is reported as an ingredient of Foli Doce in the following countries:

• Spain

International Drug Name Search

Diltiazem Hydrochloride

Class: Calcium-Channel Blocking Agents, Miscellaneous
VA Class: CV200
CAS Number: 33286-22-5
Brands: Cardizem, Cartia XT, Dilacor XR, Diltia XT, Dilt XR, Taztia XT, Tiazac

Introduction

Calcium-channel blocking agent; nondihydropyridine-derivative.^{271 331}

Uses for Diltiazem Hydrochloride

Angina

Used in the management of Prinzmetal variant angina and chronic stable angina pectoris.^{a 331}

Calcium channel blockers considered the drugs of choice in management of Prinzmetal variant angina.^a

Appears to be as effective as β-adrenergic blocking agents (e.g., propranolol) and/or oral nitrates in the management of chronic stable angina pectoris; however, generally should be used only when the patient cannot tolerate adequate doses of or is refractory to these drugs.^a

Management of unstable angina† in patients who have continuing or ongoing ischemia when therapy with β-blocking agents and nitrates is inadequate, not tolerated, or contraindicated and when severe left ventricular dysfunction, pulmonary edema, or other contraindications are not present.³¹⁵

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents).^{138 140 187 188 189 190 195 271 272}

Only extended-release formulations currently are recommended for management of hypertension.²⁷¹

One of several preferred initial therapies for hypertensive patients with a high risk of developing coronary artery disease, including those with diabetes mellitus.³¹⁹

Can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred for monotherapy by JNC 7.³¹⁹

Supraventricular Tachyarrhythmias

Management of supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias (PSVT) (e.g., those associated with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome) and temporary control of rapid ventricular rate in atrial flutter or fibrillation.^{237 238 239 244 245 247 250 252 253 256 257 258 262 270 331}

One of several preferred antiarrhythmic agents for the treatment of stable, narrow-complex supraventricular tachycardias (e.g., paroxysmal supraventricular tachycardia [reentry supraventricular tachycardia], ectopic or multifocal atrial tachycardia†, junctional tachycardia†) if the rhythm is not controlled by vagal maneuvers or adenosine and to control the ventricular response rate in atrial fibrillation or flutter.³³¹

AMI

Calcium-channel blocking agents have not proved beneficial in the early treatment or secondary prevention of AMI† and the possibility that they may be harmful has been raised.^{270 331}

May be used for relief of ongoing ischemia or to control rapid ventricular response with atrial fibrillation after an AMI† when β-adrenergic blocking agents are ineffective or contraindicated, but only in patients in whom there is no evidence of CHF, left-ventricular dysfunction, or AV block and only after weighing carefully the potential benefits versus risks, particularly negative inotropic effects and concerns about short-acting formulations of the drugs.^{270 331}

Hyperthyroidism

Short-term adjunctive therapy in the treatment of tachycardia and tachyarrhythmias in patients with hyperthyroidism† and/or thyrotoxicosis† in whom therapy with β-adrenergic blocking agents is contraindicated or not tolerated.^{172 173 174}

Diltiazem Hydrochloride Dosage and Administration

Administration

Administer by direct IV injection, continuous IV infusion, or orally.^{138 187 190 237 270 271 323 331}

Oral Administration

Conventional Tablets

Administer tablets orally 3–4 times daily before meals and at bedtime.¹⁰⁰

Extended-release Capsules

Administer orally; directions for administration (e.g., frequency, whether to administer with or without food, potential for opening capsules and mixing with food) may vary by manufacturer and formulation; consult specific manufacturer's information for additional information.

Cardizem CD, Dilacor XR, Dilt-XR, Tiazac, Taztia XT, Cartia XT, or Diltia XT may be administered once daily;^{187 190 271 278 324 325 326} diltiazem hydrochloride extended-release capsules (12 hours) are administered twice daily.^b

Cardizem CD and Cartia XT may be administered without regard to meals.^{188 325} However, Dilacor XR, Diltia XT, and Dilt-XR should be taken on an empty stomach, swallowed whole and not opened, chewed, or crushed.^{190 278 324}

Tiazac and Taztia XT may be opened and the entire contents sprinkled on a small amount of applesauce (not hot) immediately prior to administration; subdividing the contents of capsules is not recommended.^{305 326} Swallow the entire mixture without chewing.^{305 326} Immediately drink a glass of cool water to ensure that all of the mixture is swallowed.^{305 326} Do not store the sprinkle/food mixture for use at a later time.^{305 326}

Extended-release Tablets

Administer orally once daily without regard to meals.³²³ Tablet should be swallowed whole and not chewed or crushed.³²³

IV Injection

Monitor ECG and BP continuously during IV administration.²³⁷

Reconstitution

Prepare solutions from the powder for injection (Lyo-Ject) according to the manufacturer's directions.^{237 293}

Dilution

Injection solutions containing 5 mg/mL or powder for injection that has been reconstituted according to manufacturer's directions may be administered by direct IV injection without any further dilution.²³⁷

Rate of Administration

Administer over 2 minutes.²³⁷

IV Infusion

Reconstitution

Prepare solutions from the powder for injection (Lyo-Ject) according to the manufacturer's directions.^{237 293}

Dilution

Dilute 5 mg/mL injection solution or reconstituted powder for injection in the appropriate volume of a compatible infusion solution (i.e., 0.9% sodium chloride, 5% dextrose, or 5% dextrose and 0.45% sodium chloride) to produce a final diltiazem hydrochloride concentration of 1, 0.83, or 0.45 mg/mL, respectively.²³⁷

Dilution of Commercially Available Injection or Reconstituted Lyo-Ject 5 mg/mL solution.237

Quantity of 5 mg/mL Solution	Diluent Volume	Final Concentration
25 mL	100 mL	1 mg/mL
50 mL	250 mL	0.83 mg/mL
50 mL	500 mL	0.45 mg/mL

Rate of Administration

Usually 10 mg/hour; however, may range from 5–15 mg/hour.²³⁷

Dosage

Available as diltiazem hydrochloride; dosage expressed in terms of the salt.^{179 236 237}

Adults

Prinzmetal Variant Angina

Conventional Tablets

Oral

Initially, 30 mg 4 times daily.¹⁰⁰ Increase gradually at 1- to 2-day intervals until optimum control is obtained. Usual maintenance dosage is 180–360 mg daily.¹⁰⁰ After manifestations are controlled, reduce dosage to lowest level that will maintain relief of symptoms.^a

Extended-release Capsules

Oral

Initially, 120 or 180 mg once daily when administered as extended-release capsules (Cardizem CD, Cartia XT).^{187 325} Individualize dosage based on response; titrate dosage increases over 7–14 days.^{187 325} Some patients may respond to higher dosages of up to 480 mg once daily.^{187 325}

Chronic Stable Angina

Conventional Tablets

Oral

Initially, 30 mg 4 times daily.¹⁰⁰ Increase gradually at 1- to 2-day intervals until optimum control is obtained. Usual maintenance dosage is 180–360 mg daily.¹⁰⁰ After manifestations are controlled, reduce dosage to lowest level that will maintain relief of symptoms.^a

Extended-release Capsules

Oral

Initially, 120 (Dilacor XR, Diltia XT, Dilt-XR) or 120–180 mg (Cardizem CD, Cartia XT, Tiazac, Taztia XT) once daily when administered as extended-release capsules.^{187 190 274 278 324 325 326} Individualize dosage based on response; titrate dosage increases over 7–14 days.^{187 190 274 278 324 325 326} Some patients may respond to higher dosages of up to 480 (Cardizem CD, Cartia XT, Dilacor XR, Diltia XT, Dilt-XR) to 540 mg (Tiazac, Taztia XT) once daily.^{187 190 274 278 324 325 326}

Extended-release Tablets

Oral

Initially, 180 mg once daily when administered as extended-release tablets (Cardizem LA).³²³ Individualize dosage based on response; titrate dosage increases over 7–14 days.³²³ Some patients may respond to higher dosages of up to 360 mg once daily.³²³

Hypertension

Extended-release Capsules

Oral

Maximum hypotensive effect associated with a given dosage level usually is observed within 14 days.^{138 187 274 275 325 326}

JNC 7 recommends a usual maximum dosage of 420 mg daily for these preparations.³¹⁹

Recommended Dosages for Management of Hypertension

Preparation	Initial Dosage	Usual Maintenance Dosage
Cardizem LA	180–240 mg once daily323	120–540 mg323
Cardizem CD	180–240 mg once daily187	240–360 mg daily187
Cartia XT	180–240 mg once daily325	240–360 mg daily325
Dilacor XR	180–240 mg once daily190	180–480 mg once daily190
Diltia XT	180–240 mg once daily278	180–480 mg once daily278
Diltiazem hydrochloride extended-release capsules (12 hours)	60–120 mg twice dailyb	240–360 mg dailyb
Dilt-XR	180–240 mg once daily324	180–480 mg once daily324
Tiazac	120–240 mg once daily274	120–540 mg once daily274
Taztia XT	120–240 mg once daily326	120–540 mg once daily326

Switching to Cardizem CD Extended-release Capsules

Oral

Patients whose BP is adequately controlled with diltiazem therapy (as tablets or other extended-release capsules) alone or in combination with another antihypertensive agent may be safely switched to Cardizem CD or Cartia XT extended-release capsules or Cardizem LA extended-release tablets at the nearest equivalent daily dosage.^{187 323 325} Subsequent titration of dosage is based on the clinical response of the patient.^{187 323 325}

Conventional Tablets†

Oral

Initially, 30 mg 3 times daily; may be increased to a maximum dosage of 360 mg daily given in 3 or 4 divided doses.^{140 195}

Extended-release Tablets

Oral

Initially, 180–240 mg daily; however, some patients may respond to a lower dosage.³²³ Individualize dosage based on response; maximum hypotensive effect associated with a given dosage level usually is observed within 14 days.³²³ Usual maintenance dosage is 120–540 mg daily;³²³ however, JNC 7 recommends a usual maximum dosage of 420 mg daily.³¹⁹

Supraventricular Tachyarrhythmias

Paroxysmal Supraventricular Tachycardia, Junctional Tachycardia†, Ectopic Tachycardia†, Multifocal Atrial Tachycardia†)

IV

Initially, 15–20 mg (or 0.25 mg/kg) by direct IV injection over 2 minutes.^{237 256 270 331} If response is inadequate (i.e., conversion to normal sinus rhythm does not occur) give a second dose of 20–25 mg (or 0.35 mg/kg) 15 minutes after the initial dose.^{237 257 270 331}

Maintenance infusion: 5–15 mg/hour; titrate dose to heart rate.³³¹

Patients with low body weights should be dosed on a mg/kg basis.²³⁷

Ventricular Rate Control in Atrial Fibrillation and Flutter

IV

Initially, 15–20 mg (or 0.25 mg/kg) by direct IV injection over 2 minutes.^{237 270 331} If response is inadequate, give 20–25 mg (or 0.35 mg/kg) 15 minutes after the initial dose.^{237 246 270 331}

Maintenance infusion: 5–15 mg/hour; titrate dose to heart rate.³³¹

Prescribing Limits

Adults

Angina

Oral

Cardizem LA extended-release tablets: Maximum 360 mg daily.³²³

Cardizem CD, Dilacor XR, Diltia XT, Dilt-XR, and Cartia XT extended-release capsules: Maximum 480 mg daily.^{187 190 278 324 325}

Tiazac and Taztia XT extended-release capsules: Maximum 540 mg daily.^{274 326}

Hypertension

Oral

Cardizem conventional tablets†: Maximum 360 mg daily.^{140 195}

Cardizem CD and Cartia XT extended release capsules: Maximum 480 mg daily.^{187 325}

Dilt-XR, Dilacor XR, Diltia XT, Taztia XT, and Tiazac extended-release capsules and Cardizem LA extended-release tablets: maximum 540 mg daily.^{190 274 278 323 324 326 a}

However, JNC 7 recommends a usual maximum dosage of 420 mg daily for these preparations.³¹⁹

Supraventricular Tachyarrhythmias

IV

Maintenance infusion: Maximum 15 mg/hour for ≤24 hours.^{237 244 293}

Special Populations

Hepatic Impairment

Supraventricular Tachyarrhythmias

Atrial Fibrillation and Flutter

IV

Maintenance infusion: Dosage requirements may be lower.^{237 245}

Geriatric Patients

Angina

Select dosage cautiously; geriatric patients may respond to lower dosages.^{100 138 187 274 323 326 a}

Hypertension

Select dosage cautiously.^{138 187 274 323 326} The manufacturers of Dilacor XR, Dilt-XR, and Diltia XT state that patients 60 years of age or older may respond to an initial daily dosage of 120 mg.^{190 278 324}

Atrial Fibrillation and Flutter

Maintenance IV infusion: Dosage requirements may be lower.^{237 245}

Cautions for Diltiazem Hydrochloride

Contraindications

• 
  

  Contraindicated in patients with known hypersensitivity to the drug.^{237 252 253 256 258}

  
  


• 
  

  Sick sinus syndrome (unless a functioning ventricular pacemaker is in place).^{237 252 253 256 258}

  
  


• 
  

  Second- or third-degree AV block (unless a functioning ventricular pacemaker is in place).^{237 252 253 256 258}

  
  


• 
  

  Severe hypotension (SBP <90 mm Hg).^{237 252 253 256 258}

  
  


• 
  

  Oral preparations contraindicated in patients with AMI with radiographically documented pulmonary congestion.^{138 187 190 200 237}

  
  


• 
  

  IV diltiazem contraindicated in patients with cardiogenic shock.^{237 252 253 256 258}

  
  


• 
  

  IV diltiazem contraindicated in patients with VT.^{237 257}

  
  


• 
  

  IV diltiazem contraindicated in patients with atrial flutter or fibrillation with an accessory pathway (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).^{237 262}

  
  


• 
  

  IV diltiazem contraindicated if concurrent or recent (e.g., within a few hours) administration of IV β-adrenergic blockers.²³⁷

  
  

Warnings/Precautions

Warnings

Cardiac Conduction

Potential for abnormally slow heart rate (particularly in patients with sick sinus syndrome) or second- or third-degree AV block.^{100 138 187 237 274 323}

Additive effects on cardiac conduction (e.g., prolonging AV node conduction) possible with concomitant use of diltiazem with β-adrenergic blocking agents or digoxin.^{100 138 187 237 274 323}

If high-degree AV block occurs in patients with sinus rhythm receiving IV diltiazem, discontinue the drug and institute appropriate supportive measures.²³⁷

CHF

Risk of CHF, especially in those with preexisting ventricular impairment; limited experience in patients with impaired ventricular function receiving concomitant β-adrenergic blocking agents.^{100 138 187 237 251 254 256 258 274 323} Use with caution.^{100 138 187 274 323}

Hypotension

Possible symptomatic hypotension.^{100 138 187 237 274 323}

Acute Hepatic Injury

Substantial elevations in hepatic function test results (e.g., serum AST [SGOT], ALT [SGPT], LDH, alkaline phosphatase) and phenomena associated with hepatocellular injury rarely reported.^{100 138 187 237 274 323} Usually occurs early in therapy (e.g., 1–8 weeks); reversible upon discontinuation of therapy.^{100 138 187 237 274 323}

Ventricular Premature Beats

With IV administration, possible transient VPB on conversion of PSVT to sinus rhythm;²³⁷ appear to be benign and of little clinical importance.^{237 250}

Sensitivity Reactions

Possible diltiazem-induced skin eruptions with oral preparations; may infrequently progress to severe dermatologic reactions (e.g., erythema multiforme, exfoliative dermatitis).^{100 138 237} If effects persist during therapy, the drug should be discontinued.^{100 138 237} Potential for occurrence with IV administration.²³⁷

Specific Populations

Pregnancy

Category C.^{100 138 187 190 274 278 323 324 325 326}

Lactation

Distributed into milk;^{100 101 138 187 190 274 278 323 324 325 326} discontinue nursing.^{100 138 187 190 274 278 323 324 325 326}

Pediatric Use

Safety and efficacy not established.^{100 138 187 190 274 278 323 324 325 326}

Injection in single-use (Lyo-Ject) syringes contains benzyl alcohol as a preservative and should not be used in neonates.²³⁷

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.^{100 138 187 274 323 326} Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.^{100 138 187 274 323 326}

Hepatic Impairment

Use with caution.^{100 138 187 237 274 323}

Renal Impairment

Use with caution.^{100 138 187 237 274 323}

Common Adverse Effects

With oral therapy, edema, headache, dizziness, asthenia, first-degree AV block.^{138 187 274 323}

With IV therapy, hypotension, injection site reactions, vasodilation, arrhythmia.²³⁷

Interactions for Diltiazem Hydrochloride

Metabolized principally by CYP3A4.^{100 138 187 274} Inhibits CYP3A4.²⁷⁴

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors, inducers, and substrates of CYP3A4: potential pharmacokinetic interaction (altered plasma diltiazem concentrations).^{100 138 187 274 323}

Drugs Metabolized by Microsomal Enzymes

Potential pharmacokinetic interaction: altered bioavailability and/or clearance of drugs metabolized by CYP3A4.^{100 116 132 133 138 187 274}

Specific Drugs

Drug	Interaction	Comments
Anesthetics, general	Possible increased depression of cardiac contractility, conductivity, and automaticity as well as vascular dilation100 138 187 237 274 323	Titrate dosage of each drug carefully100 138 187 237 274 323
Atazanavir	Possible increased plasma diltiazem concentrations and additive effect on PR interval prolongation318	Use concomitantly with caution.318 Reduce diltiazem dosage by 50%; monitor ECG318
β-Adrenergic blockers	Potential for additive negative effects on myocardial contractility, heart rate, and prolonging AV conduction100 138 187 190 237 263 264 274 295 323 Increased plasma concentrations of propranolol and metoprolol295 296	Do not administer IV diltiazem and IV β-adrenergic blocking agents within a few hours of each other237 Propranolol dosage adjustment may be necessary when diltiazem is initiated or discontinued100
Benzodiazepines (e.g., midazolam, triazolam)	Possible increased benzodiazepine plasma concentrations and AUC resulting in increased adverse effects (e.g., prolonged sedation, respiratory depression)100 138 187 274 299 300 323
Buspirone	Increased plasma concentration and AUC of buspirone100 138 187 Potential for increased effects and toxicity of buspirone100 138 187	Dosage adjustment of buspirone may be necessary based on clinical assessments100 138 187
Carbamazepine	Possible increased serum or plasma carbamazepine concentrations and associated neurologic and sensory manifestations of carbamazepine toxicity138 200 201 202 203 204 205 206 207 208	Avoid concurrent use, if possible203 Monitor for manifestations of carbamazepine toxicity; adjust carbamazepine dosage accordingly138 200 201 202 203 204 205 206 207 208
Cyclosporine	Possible increased blood cyclosporine concentrations112 113 237 297 298 and consequent nephrotoxicity112 297 298	Monitor cyclosporine concentration in biologic fluid (especially when diltiazem therapy is initiated, adjusted, or discontinued); adjust cyclosporine dosage as needed100 138 187 237 274 275 276 291 292 297 298
Digoxin	Possible increased serum digoxin concentrations102 105 107 108 Potential for additive effects on cardiac conduction (e.g., prolonging AV node conduction)100 138 187 237 274 323	Monitor serum digoxin concentrations carefully and observe the patient closely for signs of digoxin toxicity when administered concomitantly, especially in geriatric patients, patients with unstable renal function, or those with serum digoxin concentrations in the upper therapeutic range before diltiazem is administered103 105 107 108 111 Reduce digoxin dosage if necessary103 105 107 108 111
Histamine H2-receptor antagonists (e.g., cimetidine, ranitidine)	Possible increased plasma diltiazem concentrations with concomitant administration of cimetidine100 125 126 127 Ranitidine coadministration produced smaller and not substantial alterations in diltiazem pharmacokinetics100 125 126 127	Monitor effects of diltiazem carefully when cimetidine therapy is initiated or discontinued in patients receiving diltiazem; adjust diltiazem dosage, if necessary100 126 127
HMG-CoA reductase inhibitors (e.g., lovastatin, pravastatin)	Possible increased mean AUCs and peak plasma concentrations of lovastatin with concomitant use of diltiazem and lovastatin274 301 302 Interaction not observed when diltiazem was used concomitantly with pravastatin274 302	Monitor patients receiving lovastatin concomitantly with diltiazem for evidence of lovastatin toxicity (e.g., rhabdomyolysis, myositis)301 302
Nitrates	Interaction unlikely100 187
Quinidine	Possible increased AUC and decreased clearance of quinidine100 138 187	Monitor for adverse effects of quinidine; adjust dosage accordingly100 138 187
Rifampin	Decreased bioavailability and increased clearance of diltiazem304	Avoid concomitant use; consider alternative therapy100 138 187 274 304

Diltiazem Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Following oral administration of conventional tablets, approximately 80% of a dose is rapidly absorbed from the GI tract.^a

Absolute bioavailability is about 40%; undergoes extensive first-pass metabolism.^{100 138 187 274 323}

Time to Peak Serum Concentrations Following Administration

Preparation	Time (hours)
Conventional tablets (e.g., Cardizem)	2–4100
Cardizem CD extended-release capsules	10–14187
Cardizem LA extended-release tablets	11–18323
Diltiazem hydrochloride extended-release capsules (12 hours)	6–11b

Onset

Following direct IV injection, reductions in heart rate usually occur within 3 minutes^{237 247 252} and hemodynamic effects (e.g., decrease in BP) generally occur within 2 minutes;^{237 246 247 252} effects on the AV node generally occur within minutes following initiation of a continuous IV infusion.^{237 242}

Duration

Following direct IV injection, reductions in heart rate generally persist for 1–3 hours;^{237 247 252} blood pressure reductions following direct IV injection generally are short-lived but may last 1–3 hours.²³⁷ Effects on the AV node may persist for 0.5–10 hours following a continuous IV infusion.^{237 242}

Food

Rate of absorption may be increased if Tiazac extended-release capsules are taken with a high-fat meal.²⁷⁴ Food may affect the extent of absorption of some extended-release capsules (Dilacor XR, Diltia XT).^{190 278 294}

Distribution

Extent

Rapidly and extensively distributed into body tissues.^{191 245 259}

Distributed into milk, in concentrations approximately equal to maternal serum concentrations.^{100 101 237}

Plasma Protein Binding

About 70–85% is bound to plasma proteins, but only 30–40% is bound to albumin.^{135 237 259}

Elimination

Metabolism

Rapidly and almost completely metabolized in the liver to several active and at least 5 inactive metabolites principally via CYP enzyme system, mainly CYP3A4.^{100 132 134 135 136 137 182 183 237 241 242}

Elimination Route

Excreted principally in urine as metabolites,^a with approximately 2–4% of a dose excreted unchanged.^{135 237 259}

Half-life

2–11 hours.^{191 237}

Special Populations

In geriatric patients, plasma half-life of the drug may be increased.^{191 237 239}

In patients with severe renal impairment, pharmacokinetics were unchanged.³²³

Oral clearance may be reduced and half-life prolonged in patients with liver cirrhosis.²³⁷

Stability

Storage

Oral

Conventional Tablets

Tight containers at 25°C (may be exposed to 15–30°C).^{100 a}

Protect from excessive humidity.¹⁰⁰

Extended-release Capsules

25°C (may be exposed to 15–30°C).^{138 187 274}

Protect from excessive humidity.¹³⁸

Ebexantron

Ebexantron may be available in the countries listed below.

Ingredient matches for Ebexantron

Mitoxantrone

Mitoxantrone is reported as an ingredient of Ebexantron in the following countries:

• Tunisia

Mitoxantrone dihydrochloride (a derivative of Mitoxantrone) is reported as an ingredient of Ebexantron in the following countries:

• Austria

International Drug Name Search

Doxycycline Dopharma

Doxycycline Dopharma may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Doxycycline Dopharma

Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxycycline Dopharma in the following countries:

• Belgium

International Drug Name Search

Diclac Lipogel

Diclac Lipogel may be available in the countries listed below.

Ingredient matches for Diclac Lipogel

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclac Lipogel in the following countries:

• Switzerland

International Drug Name Search

Opeazitro

Opeazitro may be available in the countries listed below.

Ingredient matches for Opeazitro

Azithromycin

Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of Opeazitro in the following countries:

• Vietnam

International Drug Name Search

Bio-Quinone Q10

Bio-Quinone Q10 may be available in the countries listed below.

Ingredient matches for Bio-Quinone Q10

Ubidecarenone

Ubidecarenone is reported as an ingredient of Bio-Quinone Q10 in the following countries:

• Latvia

International Drug Name Search

Histalen

Histalen may be available in the countries listed below.

Ingredient matches for Histalen

Cetirizine

Cetirizine is reported as an ingredient of Histalen in the following countries:

• Chile

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Histalen in the following countries:

• Chile

International Drug Name Search

Sulpirid-RPh

Sulpirid-RPh may be available in the countries listed below.

Ingredient matches for Sulpirid-RPh

Sulpiride

Sulpiride is reported as an ingredient of Sulpirid-RPh in the following countries:

• Germany

International Drug Name Search

Salbumol

Salbumol may be available in the countries listed below.

Ingredient matches for Salbumol

Salbutamol

Salbutamol is reported as an ingredient of Salbumol in the following countries:

• Tunisia

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salbumol in the following countries:

• France

International Drug Name Search

Softin

Softin may be available in the countries listed below.

Ingredient matches for Softin

Bromopride

Bromopride is reported as an ingredient of Softin in the following countries:

• Taiwan

International Drug Name Search

Rilménidine EG

Rilménidine EG may be available in the countries listed below.

Ingredient matches for Rilménidine EG

Rilmenidine

Rilmenidine dihydrogen phosphate (a derivative of Rilmenidine) is reported as an ingredient of Rilménidine EG in the following countries:

• France

International Drug Name Search

Ergocalciferolo

Ergocalciferolo may be available in the countries listed below.

Ingredient matches for Ergocalciferolo

Ergocalciferol

Ergocalciferolo (DCIT) is known as Ergocalciferol in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Diclofenac dietilamino

Diclofenac dietilamino may be available in the countries listed below.

Ingredient matches for Diclofenac dietilamino

Diclofenac

Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Diclofenac dietilamino in the following countries:

• Venezuela

International Drug Name Search

S.E.Z. Drinking Water Solution

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for S.E.Z. Drinking Water Solution

Sulfaethoxypyridazine

Sulfaethoxypyridazine is reported as an ingredient of S.E.Z. Drinking Water Solution in the following countries:

• United States

International Drug Name Search

Dexrazoxane Hydrochloride

Ingredient matches for Dexrazoxane Hydrochloride

Dexrazoxane

Dexrazoxane Hydrochloride (BANM) is known as Dexrazoxane in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)

Click for further information on drug naming conventions and International Nonproprietary Names.

Urotan

Urotan may be available in the countries listed below.

Ingredient matches for Urotan

Nalidixic Acid

Nalidixic Acid is reported as an ingredient of Urotan in the following countries:

• Peru

International Drug Name Search

Opetarl

Opetarl may be available in the countries listed below.

Ingredient matches for Opetarl

Cilostazol

Cilostazol is reported as an ingredient of Opetarl in the following countries:

• Japan

International Drug Name Search

betaine

BEE-ta-een

Commonly used brand name(s)

In the U.S.

• Cystadane

Available Dosage Forms:

• Powder for Suspension


• Tablet

Therapeutic Class: Digestant

Uses For betaine

Betaine is used to treat a lack of or defect in certain enzymes that causes too much homocysteine in the blood and urine. betaine removes the extra homocysteine from the body.

betaine is available only with your doctor's prescription.

Before Using betaine

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For betaine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to betaine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

betaine has been tested in children and, in effective doses, has not been shown to cause different side effects or problems than it does in adults. However, children may require more frequent changes in their dose than adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing the use of betaine in the elderly with use in other age groups.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of betaine

Betaine powder should be mixed with 4 to 6 ounces of juice, milk, or water until completely dissolved. The solution should be used immediately after mixing.

Do not use if the powder does not dissolve completely or gives a colored solution.

Betaine should be taken with meals.

It is important that you follow any special instructions from your doctor, such as taking folic acid, pyridoxine (vitamin B 6), and vitamin B 12 supplements. If you have any questions about this, check with your doctor.

Dosing

The dose of betaine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of betaine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (powder for solution):
  
  • To prevent buildup of homocysteine:
    
    • Adults, teenagers, and children 3 years of age and older—The starting dose is usually 3 grams taken two times a day with meals. Your doctor may adjust your dose as needed.
    
    
    • Children younger than 3 years of age—The dose is based on body weight and must be determined by your doctor. Betaine should be taken with meals.
    
    
  
  

Missed Dose

If you miss a dose of betaine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Precautions While Using betaine

Your doctor should check your progress at regular visits to make sure that betaine is working properly.

betaine Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

• Diarrhea


• nausea


• stomach upset

Betaine may cause a body odor. Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More betaine resources

• Betaine Side Effects (in more detail)
• Betaine Use in Pregnancy & Breastfeeding
• Betaine Support Group
• 0 Reviews for Betaine - Add your own review/rating

• betaine Concise Consumer Information (Cerner Multum)


• Betaine Powder MedFacts Consumer Leaflet (Wolters Kluwer)


• Cystadane Prescribing Information (FDA)

Compare betaine with other medications

• Nonalcoholic Fatty Liver Disease